Intranasal Bevacizumab for HHT-Related Epistaxis

• Status: Completed
• Trial end date: 2020-01-23
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, controlled, double-blind, placebo-controlled trial of intranasal Avastin (bevacizumab) injection versus saline control for control of HHT-related epistaxis when used in conjunction with bipolar electrocautery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

1. The patient carries a diagnosis of hereditary hemorrhagic telangiectasia (HHT)

2. The patient is to undergo treatment with electrocautery in the operating room under endoscopic visualization

3. The patient is able to give informed consent

4. The patient is at least 18 years old

Exclusion Criteria:

1. The patient has had prior treatment with systemic or nasal bevacizumab within the past year

2. The patient has undergone electrocautery for epistaxis within the 6 months prior to study enrollment

3. The patient is a minor

4. The patient is pregnant

5. The patient is incapable of understanding the consent process

6. The patient has a history of HIV or another known cause of immunosuppression, or is actively taking immunosuppressive medications due to organ transplantation, rheumatoid disease, or other medical conditions.